Krishna Institute of Medical Sciences Limited (KIMS) has announced the acquisition of a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP, located in Sangli. The acquisition, valued at up to ₹15 crore, is considered a strategic investment to expand KIMS’s reach in quaternary care facilities. The transaction was finalized on October 29, 2026, with definitive agreements signed and consideration remitted.
KIMS Strengthens Presence with Strategic Acquisition
Krishna Institute of Medical Sciences Limited (KIMS) has finalized a strategic acquisition, purchasing a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli). The announcement, made on October 29, 2026, marks a significant step in KIMS’s expansion strategy within the healthcare sector.
Deal Details and Rationale
The acquisition was approved by the Board of Directors for an aggregate consideration not exceeding ₹15 crore. This investment is viewed as a strategic move, aiming to enhance KIMS’s portfolio of quaternary care facilities. Ushahkal Abhinav Specialty Hospital LLP, founded in 2022, is a modern facility with a current capacity of 316 beds and potential for expansion.
The transaction was based on a valuation report by BDO Valuation Advisory LLP, dated October 05, 2026. The acquisition was conducted through a primary infusion of funds. The entity being acquired operates in the Healthcare Industry and is not considered a related party transaction.
Target Entity Overview
Ushahkal Abhinav Specialty Hospital LLP, based in Sangli, Maharashtra, is a quaternary care facility. For the financial year FY 2025-26, it reported a turnover of ₹80.42 crore, with a Profit After Tax (PAT) of -₹23.59 crore and a Networth of ₹116.42 crore. The company was incorporated on November 25, 2016.
KIMS has committed to this acquisition as a strategic investment, indicating a belief in the growth potential and operational synergy with the target entity. This move is expected to further solidify KIMS’s position as a leading healthcare provider in its operating regions.
Source: BSE
